Top 20 Biomanufacturing & CDMO Providers 2026

This report forms part of the Ranking News Healthcare Ranking series, which evaluates hospitals, medical institutions, pharmaceutical organizations, medical technology companies, diagnostics providers, laboratories, precision medicine platforms, pharmaceutical services providers, and healthcare systems across global healthcare markets.

Biomanufacturing and Contract Development and Manufacturing Organization providers occupy a critical position within the pharmaceutical and biotechnology ecosystem. These organizations provide the development, manufacturing, analytical, fill-finish, packaging, and supply-chain infrastructure required to transform therapeutic candidates into clinical and commercial medicines.

Unlike pharmaceutical companies that primarily own drug assets, CDMO providers support sponsors across process development, cell-line development, microbial fermentation, mammalian cell culture, viral vector manufacturing, plasmid DNA, mRNA, antibody-drug conjugates, sterile fill-finish, lyophilization, oral solid dosage, injectable manufacturing, analytical testing, quality control, and commercial supply. Their relevance is determined not only by manufacturing capacity, but also by regulatory track record, quality systems, technology transfer capability, modality coverage, and long-term sponsor trust.

The sector has become strategically important as pharmaceutical companies increasingly outsource manufacturing to specialized partners. Biologics, vaccines, cell and gene therapies, GLP-1 medicines, antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals, and complex injectables all require sophisticated manufacturing systems that many sponsors cannot build quickly or efficiently on their own.

This ranking identifies biomanufacturing and CDMO providers whose platforms demonstrate sustained relevance across biologics, advanced therapeutics, sterile manufacturing, development services, commercial-scale production, analytical capability, and global supply resilience. Rather than focusing only on revenue or facility count, the objective is to recognize organizations whose manufacturing platforms remain structurally important within the global healthcare ecosystem.

Market Overview

The biomanufacturing and CDMO market continues to expand as pharmaceutical and biotechnology companies rely on outsourced manufacturing partners to manage complexity, capacity, speed, and regulatory execution. Sponsors increasingly seek partners capable of supporting the full development-to-commercialization continuum, from early process development and clinical manufacturing to validation, regulatory inspection readiness, and commercial supply.

The market is led by large global platforms such as Lonza, Samsung Biologics, WuXi Biologics, Catalent, Thermo Fisher Scientific, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim BioXcellence, AGC Biologics, Siegfried, Recipharm, and other specialist CDMOs. Industry reporting has continued to identify Lonza, Samsung Biologics, WuXi Biologics, Catalent, and FUJIFILM Diosynth among global leaders in biologics and contract manufacturing, reflecting the increasing concentration of demand around scaled providers.

Biologics remain the most important growth driver. Monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, recombinant proteins, and cell-culture-based products require large-scale bioreactor capacity, validated processes, high-quality analytical methods, and strict regulatory compliance. WuXi Biologics reported record 2025 results, including RMB 21.8 billion in revenue, 209 new integrated projects signed, and a total integrated project count of 945, illustrating the scale of demand for biologics CRDMO services.

Capacity expansion remains a major theme. FUJIFILM Diosynth Biotechnologies has pursued a global CDMO ecosystem expansion, including large-scale investment in Hillerød, Denmark, and Holly Springs, North Carolina. Its Hillerød expansion includes additional 20,000-liter bioreactors and downstream processing streams, while the broader program has been described as part of an $8 billion-plus global manufacturing investment drive.

The market is also being reshaped by major transactions. Novo Holdings completed its acquisition of Catalent in a transaction valued at approximately $16.5 billion, with three Catalent sites to be sold to Novo Nordisk, underscoring the strategic importance of fill-finish and injectable capacity in the global pharmaceutical supply chain.

Industry Trend — 2026

The biomanufacturing and CDMO industry in 2026 is shaped by five major trends: biologics capacity concentration, advanced therapeutic manufacturing, fill-finish scarcity, geopolitical supply-chain diversification, and quality-driven sponsor selection.

First, biologics capacity continues to concentrate around scaled global providers. Large pharmaceutical companies and biotechnology sponsors increasingly prefer CDMO partners that can support process development, clinical manufacturing, late-stage scale-up, process performance qualification, and commercial manufacturing across multiple geographies. Lonza’s 2025 annual report described its transformation into a leading pure-play CDMO following the carve-out and sale process for its Capsules & Health Ingredients business, reflecting a sharper focus on contract manufacturing and development services.

Second, advanced therapeutics are creating new manufacturing requirements. Cell therapy, gene therapy, viral vectors, plasmid DNA, mRNA, and antibody-drug conjugates require specialized facilities, high-containment processes, complex analytics, cold-chain logistics, and regulatory expertise. AGC Biologics describes itself as a global CDMO offering development and manufacturing for protein expression biologics, plasmid DNA, mRNA, viral vectors, and genetically engineered cells, illustrating the sector’s movement toward multi-modality manufacturing platforms.

Third, sterile fill-finish remains strategically valuable. Injectable medicines, GLP-1 therapies, biologics, vaccines, and advanced therapeutics all depend on reliable fill-finish capacity. The Catalent transaction demonstrated how valuable sterile manufacturing sites have become for large pharmaceutical companies seeking supply-chain flexibility and capacity security.

Fourth, geopolitical diversification is becoming more important. Sponsors increasingly consider regional supply security, U.S.-China policy risk, European manufacturing resilience, and redundancy across continents. This creates opportunities for providers with strong footprints in North America, Europe, and Asia, but also increases scrutiny for companies exposed to geopolitical friction.

Fifth, quality systems and regulatory execution remain decisive. Biomanufacturing failures can delay clinical trials, disrupt commercial supply, trigger regulatory action, and damage sponsor reputations. As a result, sponsors increasingly prioritize CDMOs with strong inspection histories, quality cultures, deviation management systems, and proven commercial manufacturing experience.

Methodology — Core Eligibility Criteria

To ensure structural consistency within the category, organizations considered for this ranking were evaluated based on the following eligibility conditions:

• Operates primarily as a CDMO, CMO, biomanufacturing provider, pharmaceutical manufacturing services company, or integrated development and manufacturing partner
• Provides services such as process development, biologics manufacturing, cell and gene therapy manufacturing, sterile fill-finish, oral solid dosage manufacturing, API manufacturing, analytical testing, packaging, or commercial supply
• Maintains meaningful institutional scale through multi-site operations, global manufacturing networks, regulatory approvals, commercial manufacturing experience, or advanced modality capability
• Demonstrates relevance in pharmaceutical outsourcing, biotechnology development, biologics production, advanced therapeutics, injectable manufacturing, or commercial drug supply
• Maintains systems for GMP compliance, quality assurance, regulatory inspection readiness, technology transfer, supply-chain controls, and validated manufacturing processes

Pure equipment suppliers, laboratory-only testing companies, raw material suppliers, drug developers without meaningful contract manufacturing services, and early-stage manufacturing startups without substantial operating scale were generally excluded.

Methodology — Ranking Factors

Organizations included in the ranking were evaluated using a combination of qualitative and structural considerations rather than short-term revenue alone. Key factors considered include:

• Scale and geographic reach of CDMO and biomanufacturing operations
• Breadth of biologics, small molecule, sterile, fill-finish, cell and gene therapy, and advanced therapeutic capabilities
• Commercial manufacturing experience and regulatory inspection track record
• Process development, scale-up, analytical, and technology transfer expertise
• Ability to support clinical through commercial manufacturing
• Capacity investments, modality diversification, and supply-chain resilience
• Sponsor relationships, quality reputation, and operational reliability
• Institutional stability, brand reputation, and long-term platform relevance

The objective of the ranking is to identify biomanufacturing and CDMO providers whose platforms maintain sustained relevance within the global healthcare and life sciences ecosystem.

The Healthcare Ranking Top 20 Biomanufacturing & CDMO Providers 2026 ranking evaluates organizations based on manufacturing scale, modality coverage, regulatory capability, sponsor relevance, quality systems, and long-term institutional resilience.

The ranking universe consisted of approximately 130 biomanufacturing and CDMO providers globally, from which 20 organizations were selected for inclusion.

Tier classifications reflect relative institutional positioning within the biomanufacturing and CDMO sector and do not represent sponsor procurement advice, investment recommendations, or regulatory endorsements.

---

Tier I — Leading Global Biomanufacturing & CDMO Providers

Lonza

• Headquarters: Basel, Switzerland
• Founded: 1897
• Core focus: Biologics, small molecules, cell and gene therapy, capsules, advanced manufacturing

Lonza is one of the world’s leading CDMO providers and a benchmark institution in biomanufacturing. The company supports pharmaceutical and biotechnology sponsors across biologics, small molecules, cell and gene therapy, drug product services, microbial manufacturing, mammalian cell culture, and advanced therapeutic manufacturing.

Lonza’s strength lies in its combination of scale, technical depth, regulatory experience, and sponsor trust. It has long served as a major outsourcing partner for complex biologics and specialty medicines, supporting both clinical development and commercial supply. The company’s recent strategic shift toward a more focused CDMO identity reinforces its importance as a pure-play manufacturing and development partner.

Its biologics platform remains especially important. Monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and recombinant proteins require deep process development capability and commercial manufacturing discipline. Lonza’s ability to support these programs across global sites gives it a central position within the biopharmaceutical outsourcing market.

Lonza’s transformation into a more focused CDMO platform, broad modality coverage, commercial manufacturing track record, and quality reputation support its position as a Tier I biomanufacturing and CDMO provider in 2026.

Samsung Biologics

• Headquarters: Incheon, South Korea
• Founded: 2011
• Core focus: Large-scale biologics manufacturing, development services, antibody production, fill-finish

Samsung Biologics is one of the most important biologics CDMO providers globally and a defining player in large-scale mammalian cell culture manufacturing. The company has built a highly standardized, large-capacity manufacturing platform in South Korea, serving major pharmaceutical and biotechnology clients across biologics development and commercial supply.

Samsung Biologics’ strength lies in scale, execution, and standardization. Its manufacturing campus in Songdo has become one of the largest biologics manufacturing platforms in the world, with a business model centered on operational efficiency, quality systems, and large-volume production.

The company has continued to expand its capabilities beyond contract manufacturing into development services and broader biopharmaceutical support. Its 2025 business report emphasized sustained growth, strategic transformation, and execution based on standardization, simplification, and scalability.

Samsung Biologics’ biologics manufacturing capacity, global sponsor relationships, quality systems, and execution-oriented operating model support its position among the leading global CDMO providers.

WuXi Biologics

• Headquarters: Wuxi / Hong Kong, China
• Founded: 2010
• Core focus: Biologics CRDMO, antibody discovery, development, manufacturing, bispecifics, ADCs

WuXi Biologics is one of the leading global biologics CRDMO providers, offering end-to-end services across biologics discovery, development, clinical manufacturing, commercial manufacturing, and regulatory support. Its integrated research-development-manufacturing model gives it a differentiated position in the biologics outsourcing market.

The company’s strength lies in project breadth and technical integration. WuXi Biologics supports monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates, recombinant proteins, and other biologic modalities. Its 2025 results reported 945 integrated projects, 209 new integrated projects signed, 28 completed process performance qualifications, and total backlog of $23.7 billion, showing the depth of its pipeline and sponsor base.

WuXi Biologics is especially relevant for emerging biotechnology companies that require integrated discovery-to-manufacturing support, as well as for larger sponsors seeking flexible biologics capacity. Its platform can support early development, IND-enabling work, late-stage manufacturing, and commercial readiness.

Geopolitical risk remains a monitoring factor given the company’s China origin and U.S.-China life sciences policy uncertainty. Nevertheless, WuXi Biologics’ technical capabilities, project scale, CRDMO model, and biologics specialization support its Tier I position.

Catalent

• Headquarters: Somerset, United States
• Founded: 2007
• Core focus: Drug development, biologics, sterile fill-finish, oral dosage, softgel, clinical supply, packaging

Catalent is one of the most important global CDMO providers, with broad capabilities across biologics, sterile fill-finish, oral solid dose, softgel technologies, clinical supply services, packaging, and advanced delivery formats. The company’s platform serves pharmaceutical, biotechnology, and consumer health clients across development and commercial supply.

Catalent’s strategic importance has been reinforced by the Novo Holdings acquisition. The transaction, valued at approximately $16.5 billion, highlighted the market value of Catalent’s manufacturing network and especially its injectable and fill-finish capabilities.

The company’s strength lies in breadth. Catalent is not limited to a single modality; it supports biologics, small molecules, sterile injectables, oral dose forms, advanced delivery technologies, clinical trial supply, and commercial packaging. This makes it relevant to sponsors seeking integrated development and supply support.

Although ownership changes and site divestitures create strategic transition risk, Catalent remains a major license-targetable operating entity with substantial CDMO infrastructure. Its global network, fill-finish relevance, development services, and commercial supply capabilities support its Tier I position.

FUJIFILM Diosynth Biotechnologies

• Headquarters: College Station, United States / Billingham, United Kingdom / Hillerød, Denmark
• Founded: 2011
• Core focus: Biologics, vaccines, advanced therapies, microbial manufacturing, mammalian cell culture

FUJIFILM Diosynth Biotechnologies is one of the fastest-rising global biomanufacturing and CDMO providers, with major capabilities in biologics, vaccines, advanced therapies, microbial fermentation, mammalian cell culture, process development, and commercial manufacturing.

The company’s strength lies in long-term investment and global capacity expansion. FUJIFILM has invested heavily in creating a global CDMO ecosystem, including large-scale biologics capacity in Denmark and the United States. Its Hillerød expansion brought new production capacity into operation, while its North Carolina facility represents one of the most important new large-scale biomanufacturing investments in the United States.

FUJIFILM Diosynth is especially relevant because it combines biologics manufacturing with a broader corporate commitment from FUJIFILM Holdings to life sciences and bioprocessing. This long-term investment orientation gives the company credibility with sponsors seeking capacity security and technical partnership.

Its global expansion, biologics capability, advanced therapy relevance, and large-scale investment program support its position as a leading global biomanufacturing and CDMO provider.

---

Tier II — Established Biomanufacturing & CDMO Providers

(Alphabetical order)

AGC Biologics

• Headquarters: Seattle, United States
• Founded: 2001
• Core focus: Biologics, plasmid DNA, mRNA, viral vectors, cell therapy, microbial and mammalian manufacturing

AGC Biologics is a global biopharmaceutical CDMO providing development and manufacturing services across biologics and advanced modalities. Its services include protein expression biologics, plasmid DNA, mRNA, viral vectors, and genetically engineered cells.

The company’s strength lies in modality breadth. As sponsors increasingly develop biologics, cell and gene therapies, and nucleic-acid-based medicines, CDMO partners that can support multiple advanced platforms are becoming more important. AGC Biologics’ global footprint and advanced modality orientation position it well within this trend.

Its expansion in Japan, including additional capability in Yokohama for gene and cell therapies, mRNA pharmaceuticals, mammalian cell culture, and related services, reinforces its Asia-Pacific manufacturing relevance.

AGC Biologics’ multi-modality platform, global manufacturing network, and advanced therapeutic capabilities support its inclusion among established CDMO providers.

Boehringer Ingelheim BioXcellence

• Headquarters: Ingelheim am Rhein, Germany
• Founded: 1885
• Core focus: Biopharmaceutical contract manufacturing, mammalian cell culture, microbial fermentation

Boehringer Ingelheim BioXcellence is the biopharmaceutical contract manufacturing division of Boehringer Ingelheim and one of the most established biologics CDMO platforms in the world. The organization provides services across process development, technology transfer, clinical manufacturing, commercial manufacturing, mammalian cell culture, and microbial fermentation.

The platform’s strength lies in its long biotechnology manufacturing history and integration within a major privately held pharmaceutical company. Boehringer Ingelheim BioXcellence describes itself as a trusted biologics CDMO partner for biopharmaceutical contract manufacturing, and its 2025 activities included continued manufacturing agreements and service expansion.

Its experience in biologics manufacturing makes it especially relevant for sponsors seeking high-quality production of monoclonal antibodies, recombinant proteins, and related therapeutic biologics. The company’s pharmaceutical heritage also supports strong quality culture and regulatory execution.

Boehringer Ingelheim BioXcellence’s biologics experience, global facilities, manufacturing credibility, and sponsor-facing CDMO identity support its position among established biomanufacturing providers.

Recipharm

• Headquarters: Stockholm, Sweden
• Founded: 1995
• Core focus: Pharmaceutical CDMO, sterile fill-finish, inhalation, oral solids, biologics-adjacent services

Recipharm is a European CDMO with a broad pharmaceutical manufacturing platform spanning sterile manufacturing, oral solid dose, inhalation products, analytical services, development, and commercial supply. The company serves pharmaceutical and biotechnology sponsors across multiple dosage forms and therapeutic categories.

Recipharm’s strength lies in its diversified manufacturing network and European operating base. It is particularly relevant in sterile fill-finish, inhalation, and complex formulation services, where sponsors require specialized technical execution and regulatory experience.

The company’s platform is broader than pure biologics manufacturing. Its relevance in this ranking comes from its CDMO role across pharmaceutical manufacturing, development support, and commercial supply. As sponsors seek reliable European manufacturing partners, Recipharm remains a meaningful provider.

Recipharm’s multi-site platform, dosage-form breadth, European manufacturing presence, and development-to-commercial capabilities support its inclusion among established CDMO providers.

Siegfried

• Headquarters: Zofingen, Switzerland
• Founded: 1873
• Core focus: Drug substance, drug product, API manufacturing, oral solids, sterile fill-finish

Siegfried is a Swiss CDMO with strong capabilities in drug substance and drug product manufacturing, including active pharmaceutical ingredients, intermediates, oral solid dosage, sterile filling, and related development services. The company has built a strong reputation in pharmaceutical outsourcing across both chemical and finished-dose manufacturing.

Siegfried’s strength lies in its integrated small-molecule and drug product platform. While not primarily a biologics CDMO, it is highly relevant to the broader CDMO ecosystem because many pharmaceutical products require complex chemical synthesis, scale-up, formulation, and commercial supply.

The company’s European manufacturing base and long operating history give it credibility in regulated pharmaceutical production. Its services are particularly relevant for sponsors seeking API supply, dosage-form manufacturing, and lifecycle support.

Siegfried’s Swiss quality reputation, drug substance expertise, drug product capabilities, and commercial manufacturing experience support its position among established CDMO providers.

Thermo Fisher Scientific Pharma Services

• Headquarters: Waltham, United States
• Founded: 1956
• Core focus: Clinical trial supply, biologics, viral vectors, sterile manufacturing, small molecule CDMO services

Thermo Fisher Scientific Pharma Services is a major global CDMO and pharmaceutical services platform. The business supports sponsors across clinical trial supply, biologics manufacturing, sterile drug product, viral vectors, small molecule development, oral solid dosage, packaging, and commercial manufacturing.

Thermo Fisher’s strength lies in breadth and integration. The company combines life sciences tools, analytical technologies, clinical research, laboratory services, and pharmaceutical manufacturing support. This gives sponsors access to a broad ecosystem beyond traditional CDMO services.

Its biologics and viral vector capabilities are especially relevant as sponsors develop advanced modalities requiring specialized manufacturing and analytical infrastructure. Thermo Fisher’s scale also supports global clinical supply and commercial packaging operations.

Thermo Fisher Pharma Services’ global footprint, scientific infrastructure, clinical supply capabilities, and modality breadth support its inclusion among established CDMO providers.

MilliporeSigma / Merck Life Science CDMO Services

• Headquarters: Burlington, United States / Darmstadt, Germany
• Founded: 1668 parent history
• Core focus: Process development, viral vectors, biologics support, raw materials, CDMO services

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, Darmstadt, Germany, is a major life science tools and services provider with CDMO capabilities relevant to biologics, viral vectors, process development, and advanced therapeutic manufacturing support.

The platform’s strength lies in its combination of materials, technologies, and manufacturing services. Biomanufacturing depends not only on facilities but also on high-quality reagents, filtration, single-use technologies, process development tools, and analytical support. MilliporeSigma’s broader life science infrastructure gives it a distinctive role in the CDMO ecosystem.

Its CDMO services are especially relevant in viral vector and advanced modality support, where sponsors may require both technical process expertise and access to critical bioprocessing technologies.

MilliporeSigma’s life science infrastructure, advanced modality services, process development capability, and global sponsor relationships support its position among established CDMO providers.

PCI Pharma Services

• Headquarters: Philadelphia, United States
• Founded: 1967
• Core focus: Clinical trial supply, commercial packaging, sterile fill-finish, drug-device combination products

PCI Pharma Services is a major CDMO and pharmaceutical services provider focused on clinical trial supply, commercial packaging, sterile fill-finish, high-potency manufacturing support, and drug-device combination product services. The company plays a particularly important role in the later stages of pharmaceutical product development and commercialization.

PCI’s strength lies in clinical-to-commercial supply execution. Many sponsors require reliable packaging, labeling, serialization, cold-chain support, kit assembly, and commercial launch readiness. These services are critical for regulatory compliance and product availability.

The company is especially relevant in oncology, biologics, injectables, and specialty products where packaging, handling, and supply-chain precision are essential. Its sterile fill-finish expansion also increases its relevance to injectable medicines.

PCI Pharma Services’ packaging strength, clinical supply platform, sterile manufacturing capability, and commercial launch support justify its inclusion among established CDMO providers.

Piramal Pharma Solutions

• Headquarters: Mumbai, India
• Founded: 1988
• Core focus: Integrated CDMO, drug substance, drug product, antibody-drug conjugates, sterile manufacturing

Piramal Pharma Solutions is an integrated CDMO providing services across drug discovery support, process development, API manufacturing, drug product development, sterile manufacturing, high-potency APIs, and antibody-drug conjugates. The company serves global pharmaceutical and biotechnology sponsors through a multi-site international network.

Piramal’s strength lies in integrated development and manufacturing across both drug substance and drug product. Its high-potency and ADC capabilities are particularly relevant as oncology pipelines increasingly include complex conjugated therapies that require containment, linker-payload expertise, and specialized analytical support.

The company’s global presence, including operations in India, North America, and Europe, gives it relevance for sponsors seeking geographically diversified manufacturing support.

Piramal Pharma Solutions’ integrated CDMO model, oncology-relevant high-potency capabilities, ADC expertise, and global manufacturing footprint support its inclusion among established providers.

Rentschler Biopharma

• Headquarters: Laupheim, Germany
• Founded: 1927
• Core focus: Biopharmaceutical CDMO, biologics development, mammalian cell culture, commercial manufacturing

Rentschler Biopharma is a specialist biologics CDMO focused on process development, clinical manufacturing, commercial manufacturing, analytical development, and regulatory support for biopharmaceutical products. The company has a long history in biologics manufacturing and serves sponsors across Europe, North America, and other markets.

Rentschler’s strength lies in focused biologics expertise. Unlike broad pharmaceutical service providers, Rentschler is strongly aligned with mammalian-cell-derived therapeutic proteins and biologics development. This specialization can be attractive to sponsors seeking technical attention and quality execution.

Its German manufacturing base and U.S. presence give it transatlantic relevance. The company is particularly well positioned for sponsors that require biologics development and manufacturing support without necessarily using the largest global CDMO platforms.

Rentschler Biopharma’s biologics focus, technical depth, quality reputation, and clinical-to-commercial services support its inclusion among established biomanufacturing providers.

SK pharmteco

• Headquarters: Sacramento, United States / Seoul, South Korea
• Founded: 2019
• Core focus: Small molecule APIs, cell and gene therapy, viral vectors, pharmaceutical manufacturing

SK pharmteco is a global CDMO backed by SK Group, providing services across small molecule APIs, advanced intermediates, cell and gene therapy, viral vector manufacturing, and related pharmaceutical production. Its platform combines U.S., European, and Asian manufacturing assets.

SK pharmteco’s strength lies in its hybrid positioning. It is not limited to conventional API manufacturing; it has expanded into advanced therapeutic manufacturing through acquisitions and investment. This makes it relevant to sponsors seeking both chemical manufacturing and next-generation modality support.

The company’s global footprint and industrial backing provide strategic resilience. Its presence in the United States, Europe, and Asia also supports geographic diversification in an increasingly sensitive supply-chain environment.

SK pharmteco’s integrated manufacturing platform, advanced therapy exposure, and global supply-chain relevance support its position among established CDMO providers.

---

Tier III — Specialist Biomanufacturing & CDMO Providers

(Alphabetical order)

Ajinomoto Bio-Pharma Services

• Headquarters: San Diego, United States
• Founded: 2013
• Core focus: Small molecule API, drug product manufacturing, antibody-drug conjugates, sterile fill-finish

Ajinomoto Bio-Pharma Services is a CDMO providing development and manufacturing services across small molecule APIs, drug product, sterile manufacturing, high-potency compounds, and antibody-drug conjugates. The company operates as part of Ajinomoto Group and serves pharmaceutical and biotechnology sponsors globally.

Its strength lies in technical specialization across complex chemistry and dosage forms. ADC and high-potency manufacturing require containment, analytical expertise, conjugation chemistry, and regulatory discipline, making Ajinomoto relevant within oncology-focused CDMO outsourcing.

Ajinomoto Bio-Pharma Services’ technical capabilities, global ownership support, and specialty manufacturing focus support its inclusion among specialist CDMO providers.

Avid Bioservices

• Headquarters: Tustin, United States
• Founded: 1993
• Core focus: Biologics CDMO, mammalian cell culture, process development, commercial manufacturing

Avid Bioservices is a biologics CDMO focused on mammalian cell culture, process development, clinical manufacturing, commercial manufacturing, and related analytical services. The company serves biotechnology and pharmaceutical sponsors developing monoclonal antibodies, recombinant proteins, enzymes, and other biologic products.

Avid’s strength lies in focused biologics manufacturing. It is particularly relevant for sponsors seeking U.S.-based biologics capacity, development support, and flexible manufacturing partnerships.

The company’s scale is smaller than the largest global biologics CDMOs, but its specialized expertise and operating identity make it a suitable Tier III specialist provider.

Cambrex

• Headquarters: East Rutherford, United States
• Founded: 1981
• Core focus: Small molecule APIs, drug substance, analytical services, early-stage development, commercial manufacturing

Cambrex is a specialist CDMO focused on small molecule drug substance and related development services. Its capabilities include API development, process chemistry, analytical development, controlled substances, early-stage development, and commercial manufacturing.

Cambrex’s relevance lies in small molecule manufacturing, which remains essential despite the growth of biologics and advanced therapeutics. Many pharmaceutical pipelines still depend on complex chemical synthesis, scale-up, impurity control, and regulatory-grade commercial supply.

Cambrex’s long experience in API development and manufacturing supports its inclusion among specialist CDMO providers.

KBI Biopharma

• Headquarters: Durham, United States
• Founded: 1996
• Core focus: Biologics CDMO, process development, microbial and mammalian manufacturing, analytical services

KBI Biopharma is a biologics CDMO providing process development, analytical development, formulation, microbial manufacturing, mammalian cell culture, and clinical manufacturing services. The company serves biotechnology and pharmaceutical sponsors developing proteins, antibodies, and other biologics.

KBI’s strength lies in development and analytical expertise. Biologics manufacturing depends heavily on process characterization, protein analytics, formulation, and scale-up, especially during early and mid-stage development.

The company’s focused biologics platform, U.S. manufacturing base, and technical services make it an important specialist provider within the CDMO ecosystem.

Polpharma Biologics

• Headquarters: Amsterdam, Netherlands / Warsaw, Poland
• Founded: 2013
• Core focus: Biologics development, biosimilars, mammalian cell culture, commercial manufacturing support

Polpharma Biologics is a specialist biologics development and manufacturing organization with capabilities in biosimilars, mammalian cell culture, process development, analytical services, and biologics manufacturing. The company has built a strong European biologics platform with relevance in both proprietary biosimilars and contract manufacturing.

Its strength lies in biologics know-how and European manufacturing infrastructure. Biosimilars require deep comparability analytics, process discipline, regulatory understanding, and commercial manufacturing capability, all of which overlap with broader biologics CDMO requirements.

Polpharma Biologics’ European base, biologics specialization, and biosimilar development expertise support its inclusion among specialist biomanufacturing providers.

---

Remarks

Biomanufacturing and CDMO providers continue to serve as essential infrastructure for pharmaceutical and biotechnology development. Their role extends beyond manufacturing capacity into process development, quality systems, regulatory execution, analytical science, technology transfer, fill-finish, advanced modality support, and commercial supply resilience.

The organizations recognized in this ranking represent providers whose manufacturing platforms maintain sustained relevance across biologics, small molecules, advanced therapeutics, sterile injectables, cell and gene therapy, clinical supply, commercial manufacturing, and pharmaceutical outsourcing. Tier classification reflects relative institutional positioning within the biomanufacturing and CDMO sector rather than direct sponsor procurement guidance.

Tier classification reflects relative manufacturing scale, modality breadth, regulatory capability, quality reputation, sponsor relationships, capacity investment, geographic reach, and long-term platform resilience. The ranking does not constitute a procurement recommendation, investment recommendation, regulatory endorsement, or evaluation of individual manufacturing sites, scientists, or quality teams.

---

Recognition

Organizations included in the Top 20 Contract Research Organizations 2026 ranking may request information regarding authorized use of the Ranking News designation for marketing and communications purposes.

Recognized institutions may reference the designation in:

• corporate websites
• investor communications
• marketing materials
• institutional presentations
• academic and recruitment materials

Ranking inclusion is editorially determined and independent of licensing, advertising, or commercial participation. Recognition-materials licenses govern only the use of official Ranking News / Advisory Ranking assets, approved wording, and related communications materials.

Licensing inquiries:
[email protected]